Issue 2 — April 18, 2026

THIS WEEK

The FDA approved a new oral GLP-1 pill on April 1 with no food or water restrictions, a meaningful mechanistic departure from oral semaglutide that most coverage has glossed over. We break down the ATTAIN trial data and what the head-to-head comparison with oral semaglutide actually shows. On the compounding front, the FDA announced on April 15 that seven peptides including BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP will go before its advisory panel in July for review. This is not an approval. It is the beginning of a process that typically takes 6 to 12 months after committee review to reach a final FDA decision. The Regulatory Radar section this week covers exactly what that distinction means and what readers with active prescriptions should know right now.

Study of the Week

The First Oral GLP-1 With No Food or Water Restrictions

Orforglipron (Foundayo) — FDA Approved April 1, 2026

On April 1, 2026, the FDA approved orforglipron under the brand name Foundayo for adults with obesity or overweight with at least one weight-related comorbidity. It is the first oral GLP-1 receptor agonist that can be taken at any time of day without food or water restrictions. That single sentence contains a mechanistic distinction worth understanding before you read the trial numbers.

The ATTAIN Phase 3 program enrolled more than 4,500 participants across two registration trials. ATTAIN-1 enrolled 3,127 adults without diabetes. At 72 weeks, weight loss was 7.5% at the lowest studied dose, 9.3% at the mid dose, and 11.2% at the highest dose, compared to 2.1% in the placebo group. ATTAIN-2 enrolled 1,613 adults with type 2 diabetes. Weight reductions ranged from 5.1% to 9.6% versus 2.5% in the placebo group, with significant improvements in HbA1c across all doses.

These numbers are meaningful but they are not the headline. Oral semaglutide, approved in December 2025 under the brand Wegovy oral, produces comparable weight loss in the 14% to 15% range at its maximum dose. The more important difference is pharmacological: orforglipron is a small molecule, not a peptide. That distinction is what drives the no-food-restriction advantage and it is covered in full in Mechanism Corner this week.

The safety profile includes the standard GLP-1 gastrointestinal effects: nausea, constipation, diarrhea, vomiting. Orforglipron carries a boxed warning for potential thyroid C-cell tumors, consistent with the class. The higher dose showed GI discontinuation rates of up to 9.7% in the ACHIEVE-3 head-to-head trial, compared to 4.9% with oral semaglutide 14 mg. That tradeoff is real and matters for the clinical decision.

The bottom line on orforglipron: it works, it is FDA approved, and the no-food-restriction advantage is pharmacologically genuine rather than a marketing claim. It is not more effective than injectable GLP-1s or tirzepatide. It occupies a real niche for patients who want an oral option without the absorption constraints of semaglutide tablets. The access pricing is notable: as low as $25 per month with commercial insurance savings card, $149 per month self-pay at the lowest dose, and $50 per month for eligible Medicare Part D patients beginning July 1, 2026.

Full premium section continues with the ACHIEVE-3 head-to-head trial data versus oral semaglutide, dose-by-dose weight loss breakdown, tolerability comparison, and how to think about this approval in the context of the broader oral GLP-1 market.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use